Envveno Medical Corporation · NASDAQ:NVNO
Envveno Medical — Investor Presentation (July 2026)
25 slides from Envveno Medical's investor presentation, Jul 14, 2026
Slide 1: Investor Presentation July 2026
en «eno MEDICAL Investor Presentation July 2026 Breakthrough Tréai
Slide 2: Legal Disclaimers
Legal Disclaimers This presentation and any statements of stockholders, directors, employees, representatives and partners of enVVeno Medical, Inc. (the Company’) related thereto contain, or may contain, among other things, certain “forward-looking statements" within the meaning of the Private Secur
Slide 3: Changing the Treatment Paradigm for Deep Venous Disease
en¥%yeno MEDICAL Changing the Treatment Paradigm for Deep Venous Disease
Slide 4: Investment Overview
INVESTMENT OVERVIEW enVVe System: Treatment for Deep Venous Insufficiency (DVI) + Severe Deep Venous Insufficiency (DVI): * Peer-Published Health Economics to Support Progressive, Debilitating Venous Disease of the Broad Reimbursement Leg with No Current Effective Treatment Options » Ample In-House
Slide 5: Deep Venous Insufficiency (DVI): a Progressive and Debilitating Venous Disease
Deep Venous Insufficiency (DVI) occurs when insufficient blood returns to the heart and lungs due to permanently damaged values in the deep veins of the leg Severe DVI: A Progressive and Debilitating Blood pooling in lower leg Venous Disease Increased risk for PEs and DVTs Severe DVI leads to: Venou
Slide 6: A Growing Healthcare and Economic Burden
A Growing Healthcare and Economic Burden ~1.5M with venous leg ulcers (VLUs)' » | 30% » | 20-40% Unhealed 1-year ulcer ulcers at 1-year’ recurrence! ~3M Afflicted with severe DVI in the U.S." $30,000 Annual wound care cost per patient? ~$20B Si Direct medical costs? The Solution to a $20B Problem
Slide 7: DVI: Current Standard of Care is Ineffective
DVI: Current Standard of Care is Ineffective * Poor compliance ¢ Does not address the underlying disease cause + Ineffective for deep venous disease {oo Compression Garments Leg Elevation enwyeno
Slide 8: enwyeno
enwyeno MEDICAL
Slide 9: Non-Surgical Evolution of a Clinically Validated Surgical Device
Non-Surgical Evolution of a Clinically Validated Surgical Device + Transcatheter-based, minimally invasive procedure requiring no overnight hospital stay + VenoValve (surgical) lead to enVVe (non-surgical) + Improved performance, strength and durability + Three times the physician base compared to s
Slide 10: The TAVVE Procedure
envwyeno The TAVVE™ Procedure envse Venous Valve
Slide 11: First Came VenoValve: Surgical Replacement Venous Valve
First Came VenoValve: Surgical Replacement Venous Valve SAVVE study enrolled 75 patients across 21US. sites Proof of concept that a single replacement venous valve is sufficient to produce meaningful and lasting clinical benefit Validated world-wide need and demand for replacement venous valve WenoV
Slide 12: VenoValve: Substantial and Sustained Clinical Improvement
VenoValve: Substantial and Sustained Clinical Improvement rVCSS 0, of patients with average point rVCSS it it te i tients improvement 92.3% BRM trrcexepert in 74 lperevarens Msgr Pain 9, median percent Ulcer 9, inerienicer (VAS Scores) 75% improvernent Healing 87% ees enyweno (=)
Slide 13: Ulcer Healing from SAVVE Trial Patients
Ulcer Healing from SAVVE Trial Patients Untreatedleg Treated leg, 12 months enweng
Slide 14: VenoValve: PMA Non-Approvable Decision
Nasdaq: NVNO VenoValve: PMA Non-Approvable Decision Surgical Procedure Concerns and S udy Evidentiary Gaps Surgical Safety Profile Surgical Pocket Bleeding Surgical Incision Infections “FDA believes the (MAE) events constitute a substantial risk to patients as many of the MAEs required rehospitaliza
Slide 15: TAVVE: TrAnscatheter Venous Valve Endoprosthesis Pivotal Trial
TAVVE: TrAnscatheter Venous Valve Endoprosthesis Pivotal Trial Prospective, Randomized, Multi-Center Trial with No Open Surgical Safety Concerns and Measuring Both Hemodynamic Improvement and Clinical Benefit Study @ era ain | dit 12 Mo. Data | Up to 40 | ~165 subjects Design e ~55 subjects for PMA
Slide 16: TAVVE Addresses All FDA Concerns
VenoValve: PMA Non-Approvable Decision Surgical Safety Profile Mechanism of Action Potential Placebo/Study Effect Surgical Pocket Bleeding Lack of Hemodynamic Is the Valve Why Surgical Incision Infections Confirmation Patients Improved? No open surgical procedure. Hemodynamic endpoint: Randomized co
Slide 17: Stakeholder Appeal Symmetry: Patients; Physicians; Insurers
Stakeholder Appeal Symmetry: Patients; Physicians; Insurers. + Patients (want it) — Replace years of ineffective compression therapy and wound care — No open surgery, general anesthesia, or overnight hospital stay — Address the underlying cause of the disease, not just symptoms « Insurers (cover it)
Slide 18: Compelling Manufacturing and Commercial Capabilities
Compelling Manufacturing and Commercial Capabilities Manufactured by highly skilled technicians at our own 14,000 ft? Irvine facility has capacity to manufacture up to 30,000 Irvine facility with clean rooms Valves per year + Projected ASP: $30,000 + Initial Profit Margin: Elite 80’s + Revenue Capac
Slide 19: Competitive Landscape
Competitive Landscape + Multi-Year Headstart — 10 years of development — Engineering, testing, clinical data + Degree of Technical Difficulty — Decades of failed attempts — Limited bio-prosthetics know-how + Steep Regulatory Hurdle — Class Ill device — Independent clinical evidence + Broad Patent Pr
Slide 20: Recent Cardiovascular Device Exits that Defined New Markets
Recent Cardiovascular Device Exists that Defined New Markets Ojnari FlowTriever/ ClotTriever + Mechanical Thrombectomy + Venous Clot Removal PE/DVT + Minimally Invasive, Catheter-Based + Vascular Surgeons, Interventional Radiologists, Interventional Cardiologists + USTAM ~$6 Billion Acquired by: str
Slide 21: Corporate Overview
enwyeno MEDICAL Corporate Overview
Slide 22: Capital Efficient Strategy to Fund Value Generating Milestones
Capital Efficient Strategy to Fund Value Generating Milestones Interim Data Readouts at Prestigious Medical Conferences 2029 PMA Submission Q3 2026 Q4 2026 Q4 2026 Q4 2028 Begin Site Commence Early Data Full Activation Enrollment Readout Enrollment Capital Needs Align Directly With TAVVE Trial Execu
Slide 23: Proven Management Team With Broad Medical Device and Commercialization Experience
Proven Management Team With Broad Medical Device and Commercialization Experience Robert Berman (Chief Executive Officer, Director + Former CEO, Anica Biosciences (NasdaqANDX) + Former COO, Acacia Research (NasdaqACTG) + as. + JD, North Wharton, Uni. of Pennsylvania Easter Law Mare Glickman, M.D. Se
Slide 24: Collective Industry Experience
Collective Industry Board of Directors Experience: Medtronic Dr. Francis Duhay Dr. Sanjay Shrivasta + Former Chief Medical + Business Development - Officer — Edwards Johnson and Johnson fohmrenafohnven Lifesciences + 18 years— VP Marketing and + Expert in surgical and “4 Strategy, R&D Tncaleea hae v
Slide 25: Arbitrage Opportunity
Arbitrage Opportunity Low Market Value/High Intrinsic Value enywyeno MEDICAL